Drugs / Dendritic Cell Tumor Peptide Vaccine
last change Dec 2024 re-read 2 minutes ago

Dendritic Cell Tumor Peptide Vaccine

Vaccine

Developed for
diffuse glioma, H3 G34 mutant
Investigated by
Jonsson Comprehensive Cancer Center

Trials 1 · a red edge is where a trial was stopped

202520262027202820292030
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05457959 Dec 2024 → Dec 2029 diffuse glioma, H3 G34 mutant Jonsson Comprehensive Cancer Center Withdrawn No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Dendritic Cell Tumor Peptide Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT05457959
Modality Vaccine “peptide-pulsed dendritic cell vaccination” NCT05457959